drugset / Trial / NCT00908050

Study of the Safety and Efficacy of Botox in Bruxism

NCT00908050

Phase 4 Completed 23 enrolled Baylor College of Medicine Allergan · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to determine whether botulinum toxin helps patients with bruxism.

Timeline

Start
2009-04
Primary completion
2011-08
Completion
2011-09

Drugs

EvaluationDrugModalityDoseRoute
Comparator Botulinum toxin type A Protein / enzyme biologic 35 iu Intramuscular
Comparator Botulinum toxin type A Protein / enzyme biologic 60 iu Intramuscular

Indications